The risk factors and methods of minimizing the occurrence of serious rash during treatment with lamotrigine (LTG) were evaluated by an international panel of experts and by review of published and unpublished reports
Stevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocuta...
Eight patients rechallenged with lamotrigine after initial exposure which resulted in a skin rash ar...
Purpose: This postmarketing surveillance study of lamotrigine (LTG) was performed to provide complem...
AbstractPurposeWe systematically reviewed studies to provide current evidence on the incidence and r...
AbstractPurposeWe systematically reviewed studies to provide current evidence on the incidence and r...
Lamotrigine is a newer anti-epileptic drug synthesised in 1980s and approved by USFDA in 1994. It is...
INTRODUCTIONLamotrigine is used to treat a number of disease states, including bipolar disorder. It ...
Purpose Cutaneous adverse drug reactions (cADRs) are a major cause of lamotrigine (LTG) discontinuat...
Lamotrigine is an important new addition to the drugs used to treat people with seizure disorders, b...
Abstract Objective: To determine the safety of lamotrigine rechallenge after a first episode of skin...
AbstractThe aim of this study was to determine whether lamotrigine can be re-introduced safely and w...
Cutaneous rash is one of the commonest adverse events associated with lamotrigine. We assessed wheth...
Stevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocuta...
Objective: Lamotrigine is a new generation anticonvulsant, also used in bipolar type 1 disorders to ...
Objective: Lamotrigine is a new generation anticonvulsant, also used in bipolar type 1 disorders to ...
Stevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocuta...
Eight patients rechallenged with lamotrigine after initial exposure which resulted in a skin rash ar...
Purpose: This postmarketing surveillance study of lamotrigine (LTG) was performed to provide complem...
AbstractPurposeWe systematically reviewed studies to provide current evidence on the incidence and r...
AbstractPurposeWe systematically reviewed studies to provide current evidence on the incidence and r...
Lamotrigine is a newer anti-epileptic drug synthesised in 1980s and approved by USFDA in 1994. It is...
INTRODUCTIONLamotrigine is used to treat a number of disease states, including bipolar disorder. It ...
Purpose Cutaneous adverse drug reactions (cADRs) are a major cause of lamotrigine (LTG) discontinuat...
Lamotrigine is an important new addition to the drugs used to treat people with seizure disorders, b...
Abstract Objective: To determine the safety of lamotrigine rechallenge after a first episode of skin...
AbstractThe aim of this study was to determine whether lamotrigine can be re-introduced safely and w...
Cutaneous rash is one of the commonest adverse events associated with lamotrigine. We assessed wheth...
Stevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocuta...
Objective: Lamotrigine is a new generation anticonvulsant, also used in bipolar type 1 disorders to ...
Objective: Lamotrigine is a new generation anticonvulsant, also used in bipolar type 1 disorders to ...
Stevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocuta...
Eight patients rechallenged with lamotrigine after initial exposure which resulted in a skin rash ar...
Purpose: This postmarketing surveillance study of lamotrigine (LTG) was performed to provide complem...
DOI
Add to ORKG